Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising th...
Main Authors: | Nicole Scherr, Raphael Bieri, Sangeeta S. Thomas, Aurélie Chauffour, Nitin Pal Kalia, Paul Schneide, Marie-Thérèse Ruf, Araceli Lamelas, Malathy S. S. Manimekalai, Gerhard Grüber, Norihisa Ishii, Koichi Suzuki, Marcel Tanner, Garrett C. Moraski, Marvin J. Miller, Matthias Witschel, Vincent Jarlier, Gerd Pluschke, Kevin Pethe |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-12-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-07804-8 |
Similar Items
-
Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms
by: Stéphanie Bibert, et al.
Published: (2017-10-01) -
On the origin of <it>Mycobacterium ulcerans,</it> the causative agent of Buruli ulcer
by: Doig Kenneth D, et al.
Published: (2012-06-01) -
Buruli Ulcer : Mycobacterium Ulcerans Disease
Published: (2019) -
Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection With Mycobacterium ulcerans
by: Katharina Röltgen, et al.
Published: (2020-05-01) -
Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.
by: Miriam Bolz, et al.
Published: (2016-04-01)